先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02096 先声药业

未开盘 09-28 16:08:28

11.240

+0.050

+0.45%

最高11.480	最低11.180	成交量279.50万
今开11.180	昨收11.190	日振幅2.68%
总市值288.64亿	流通市值288.64亿	总股本25.68亿
成交额3,151万	换手率0.11%	流通股本25.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02096","market":"HK","secType":"STK","nameCN":"先声药业","latestPrice":11.24,"timestamp":1790582908003,"preClose":11.19,"halted":0,"volume":2795000,"delay":0,"changeRate":0.0044682752457552025,"floatShares":2568000000,"shares":2568000000,"eps":0.631338667921864,"marketStatus":"未开盘","change":0.05,"latestTime":"09-28 16:08:28","open":11.18,"high":11.48,"low":11.18,"amount":31511312,"amplitude":0.02681,"askPrice":11.24,"askSize":6000,"bidPrice":11.22,"bidSize":12000,"shortable":3,"etf":0,"ttmEps":0.7117641993410214,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790645400000},"marketStatusCode":0,"adr":0,"listingDate":1603728000000,"exchange":"SEHK","adjPreClose":11.19,"dividendRate":0.018416,"openAndCloseTimeList":[[1790559000000,1790568000000],[1790571600000,1790582400000]],"volumeRatio":0.8063590600605471,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02096","defaultTab":"news","newsList":[{"id":"1117251743","title":"先声药业2026年中期营收45.80亿元，经调整净利润9.64亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117251743","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117251743?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:40","pubTimestamp":1790239217,"startTime":"0","endTime":"0","summary":"先声药业公布2026年中期报告，报告期内营收45.80亿元人民币，同比上涨27.8%。经调整净利润9.64亿元人民币，同比提升48.7%。经营活动所得现金净额为16.05亿元，上年同期8.63亿元，增幅为85.9%。从主要治疗领域来看，神经科学领域收入20.09亿元，占比约43.9%，同比增长60.9%；抗肿瘤领域收入9.25亿元，占比20.2%，同比增长5.8%；自身免疫领域收入12.10亿元，占比26.4%，同比增长20.2%；其他业务收入4.36亿元，占比9.5%，同比增长37.8%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"先声药业2026年中期营收45.80亿元，经调整净利润9.64亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669103169","title":"【券商聚焦】兴业证券维持先声药业（02096）增持评级 指创新药高增推动盈利提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2669103169","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669103169?lang=zh_cn&edition=full","pubTime":"2026-09-23 15:12","pubTimestamp":1790147547,"startTime":"0","endTime":"0","summary":"2026年上半年，公司实现收入45.80亿元人民币，归母净利润8.29亿元人民币，经调整归母净利润9.64亿元人民币；创新药业务收入38.87亿元人民币，占总收入84.9%。神经科学收入20.09亿元人民币，占比43.9%；自身免疫收入12.10亿元人民币，占比26.4%；肿瘤领域收入9.25亿元人民币。该交易达成后，先声药业累计完成6项对外授权，潜在总交易金额超过61亿美元。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992285","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","02096","LNGR","KCE","MEDX","601377","159992","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669017165","title":"先声药业周云曙：对外授权是阶段性选择，未来不再简单追求数量","url":"https://stock-news.laohu8.com/highlight/detail?id=2669017165","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669017165?lang=zh_cn&edition=full","pubTime":"2026-09-23 10:23","pubTimestamp":1790130233,"startTime":"0","endTime":"0","summary":"国产创新药出海BD（对外授权）交易火热，“卖青苗”争议随之而来，部分本土企业将早期管线海外权益提前授权给跨国药企，这种模式可以分担研发风险、验证中国创新价值，却也存在优质资产价值被低估的隐忧。如何兼顾短期生存与长期产业收益，成为中国创新药企出海需要权衡的命题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882254548.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609233882254548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","LU2289578879.USD","LU1997244956.HKD","LU2097828631.EUR","LU0405327148.USD","LU1255011170.USD","LU1997245094.SGD","LU1064130708.USD","BK0196","LU2148510915.USD","LU2328871848.SGD","BK1583","LU2097828557.USD","LU2488822045.USD","LU2097828714.EUR","BK0012","LU1146622755.USD","BK0028","BK0239","BK1191","600276","LU0405327494.USD","LU2580892862.HKD","LU2097828474.EUR","BK0060","LU1328615791.USD","LU1781817850.SGD","LU1969619763.USD","LU1580142542.USD","LU2580892789.USD","LU1655091616.SGD","02096","LU1997245177.USD","LU2097828805.USD","BK0183","LU2495084118.USD","LU1820825898.SGD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669096130","title":"【券商聚焦】浙商证券维持先声药业（02096）买入评级 指创新药与BD共同兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2669096130","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669096130?lang=zh_cn&edition=full","pubTime":"2026-09-21 14:15","pubTimestamp":1789971349,"startTime":"0","endTime":"0","summary":"金吾财讯 | 浙商证券发布研报指，先声药业 2026H1业绩收入利润双高增，创新药与BD共同兑现，TCE资产再次授权。2026年上半年营业收入45.80亿元人民币，同比增长27.8%；归母净利润8.29亿元人民币，同比增长37.9%。经营活动现金净流入16.05亿元人民币，同比增长约86.0%。对外授权方面，截至2026H1，公司已就五项自主研发创新药物与国际药企达成合作，交易总金额超过46亿美元；2026H1确认许可收入4.05亿元人民币，上年同期1.22亿元人民币。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992106","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","IBBQ","KCE","MEDX","02096","601878","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154544158","title":"先声药业回购159.6万股股份，总额约1771.11万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154544158","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154544158?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:01","pubTimestamp":1789380064,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年9月14日发布公告，披露其于2026年9月11日于香港联交所回购159.6万股普通股，回购价格介乎每股10.98港元至11.20港元，合计支付约1771.11万港元。本次回购股份占2026年9月10日已发行股本约0.062%。公司表示，截至2026年9月11日，已发行股本维持在25.68亿股，库藏股数为0股。先声药业集团有限公司确认，本次回购已严格遵守香港联合交易所有限公司证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业回购159.6万股股份，总额约1771.11万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142091667","title":"先声药业9月11日回购159.6万股，耗资约1,771.11万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142091667","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142091667?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:25","pubTimestamp":1789122350,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年9月11日公告，公司于香港联合交易所场内回购普通股1,596,000股，占该公司当日现有已发行股本的约0.062%。本次回购每股价格介乎港币10.98元至11.20元之间，合计支付的总金额为约1,771.11万港元。回购完成后，公司已发行股本总数暂维持为2,568,198,618股。公告显示，先声药业集团有限公司股东已于2026年6月12日通过购回授权，授权公司可回购股份总数达256,819,861股。本公告由先声药业集团有限公司联席公司秘书朱达签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业9月11日回购159.6万股，耗资约1,771.11万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560799","title":"先声药业(02096)再斥资近1500万港元回购 长期主义为市场注入信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560799","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666560799?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:22","pubTimestamp":1789039323,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月10日，先声药业继续回购股份，继昨日回购92.9万股后，公司再度斥资约1424.53万港元回购126.5万股，回购价格区间在11.17至11.38港元。公司的持续动作，彰显了对股东权益的重视，以及公司坚持长期主义发展的信心。2026年上半年，公司交出了一份亮眼成绩单：总营收45.8亿元，同比增长27.8%；经调整净利润9.6亿元，同比增长48.7%；创新药收入占比攀升至85%，产品和研发能力已得到认可。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134400235","title":"先声药业：9月10日回购126.50万股，耗资约1,424.53万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134400235","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134400235?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:46","pubTimestamp":1789037177,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年9月10日发布公告，披露公司当日在香港联交所场内回购股份事宜。本次股份回购数量为1,265,000股，约占公司现有已发行股本的0.049%。每股最高回购价为港币11.38元，最低回购价为港币11.17元，合计支付金额约港币14,245,250元。公告显示，截至2026年9月10日，公司已发行股本仍保持2,568,198,618股不变，已回购的上述股份尚未被注销。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业：9月10日回购126.50万股，耗资约1,424.53万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666923567","title":"先声药业(02096.HK)9月10日斥资约1424.53万港元回购126.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666923567","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666923567?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:44","pubTimestamp":1789037097,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1583","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144157808","title":"先声药业：9月9日回购92.90万股，耗资约1070.33万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144157808","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144157808?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:16","pubTimestamp":1788949019,"startTime":"0","endTime":"0","summary":"先声药业集团有限公司于2026年9月9日公告，公司当日于香港联交所场内回购普通股92.90万股，占紧接该变动前已发行股本约0.036%。回购价格区间为每股港币11.48元至11.554元，合计支付约1070.33万港元。本次回购股份尚未注销，故公司已发行股本仍维持约25.68亿股，库藏股数量为0。公司另披露，购回授权于2026年6月12日获股东大会通过，可回购股份总数为256,819,861股，截至当日已回购股份总数达1,982,000股，占购回授权通过当日已发行股本约0.77%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业：9月9日回购92.90万股，耗资约1070.33万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666924584","title":"先声药业(02096)9月9日斥资1070.33万港元回购92.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666924584","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666924584?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:15","pubTimestamp":1788948948,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，于2026年9月9日，该公司斥资1070.33万港元回购92.9万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584921","title":"先声药业(02096.HK)9月9日斥资1070.33万港元回购92.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584921","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666584921?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:15","pubTimestamp":1788948948,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666831355","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业(02096)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831355?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:43","pubTimestamp":1788939780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中国生物制药、石药集团及科伦药业，联邦制药表现大致符合预期，而三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","03933","IE00BZ08YS42.EUR","01530","HK0000165453.HKD","BK1583","BK1161","IE00BZ08YT58.USD","BK1574","BK1593","IE00B3M56506.USD","BK1515","01477","BK1521","IE00BZ08YR35.GBP","BK1191","03692","01177","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664895633","title":"首款国产长效RSV预防单抗获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664895633","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664895633?lang=zh_cn&edition=full","pubTime":"2026-09-04 12:58","pubTimestamp":1788497911,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","02096","BK1191","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","09996","IE00B0JY6N72.USD","03759","06821","LU1242518857.USD","00013","01093","06160","01951","LU2543165471.USD","LU0039217434.USD","LU0348783233.USD","02596","06078","01548","01530","LU0856984785.SGD","LU1880383366.USD","01952","BK1161","BK1589","03329","02268","09966","06990","LU1152091168.USD","01801","BK1209","LU0588546209.SGD","02273","LU0327786744.USD","02269","HK0000306685.HKD","01276","BK1515","IE00B5MMRT66.SGD","01177","02162","HK0000320264.USD","LU0315179316.USD","SG9999004220.SGD","IE00B543WZ88.USD","KURE","LU0307460666.USD","09926","KCE","02096","LU1251922891.USD","03692"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664280009","title":"先声药业：英沐乐获药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664280009","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664280009?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:51","pubTimestamp":1788483060,"startTime":"0","endTime":"0","summary":"9月3日，先声药业（02096）发布公告，宣布其与瑞阳（山东）生物制药有限公司的战略合作项目，国产1类生物新药库莱韦拜单抗（商品名：英沐乐?）已获得中国国家药品监督管理局批准上市。该药物用于即将进入或出生在第一呼吸道合胞病毒（RSV）流行季的胎龄≥35周的新生儿和婴儿，预防RSV引起的下呼吸道感染，特定排除患有慢性肺疾病的儿童。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609043864735568.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609043864735568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","02096","IPOS","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664687715","title":"先声药业(02096.HK)：英沐乐®获国家药品监督管理局批准在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664687715","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664687715?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:32","pubTimestamp":1788442378,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02096","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120495764","title":"先声药业9月2日回购105.30万股股份，约耗资1,235.74万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120495764","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120495764?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:52","pubTimestamp":1788353554,"startTime":"0","endTime":"0","summary":"先声药业（02096）于2026年9月2日发布翌日披露报表，公司于当日在香港联交所场内回购普通股共计1,053,000股，占回购前已发行股本约0.041%。回购价格区间介乎每股11.4711港元至11.86港元，合计支付对价约12,357,390港元，折合约1,235.74万港元。\n本次回购后，先声药业的已发行股本保持在2,568,198,618股，库藏股数量为0。公司于2026年6月12日曾通过购回授权，本次回购系在相关授权下进行，公司最多可购回256,819,861股。先声药业在公告中确认已遵守香港联交所证券上市规则及相关法律法规。\n本公告由先声药业联席公司秘书朱达签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业9月2日回购105.30万股股份，约耗资1,235.74万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664143938","title":"先声药业(02096)9月2日耗资约1235.74万港元回报105.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664143938","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664143938?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:45","pubTimestamp":1788353149,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)公布，2026年9月2日耗资约1235.74万港元回报105.3万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133114746","title":"先声药业8月无新增发行或库存股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1133114746","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133114746?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:23","pubTimestamp":1788348232,"startTime":"0","endTime":"0","summary":"先声药业于2026年9月2日发布月报表，披露公司截至2026年8月31日止期间股本和股份变动情况。公告显示，先声药业在该月未发生新增股份发行或回购、注销及库藏股等活动。先声药业目前的已发行股份数量为2,568,198,618股，较上月底持平。此外，根据公告，公司确认其公众持股比例符合15.45%的最低要求。公告还披露，于2023年6月15日通过修订的受限制股份单位计划已预留235,201,361股作为潜在发行额度。本月内暂未实际新发行股份或转让库存股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.simcere.com","stockEarnings":[{"period":"1week","weight":-0.0319},{"period":"1month","weight":-0.0053},{"period":"3month","weight":0.1411},{"period":"6month","weight":-0.151},{"period":"1year","weight":-0.0802},{"period":"ytd","weight":-0.041}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0368},{"period":"3month","weight":0.077},{"period":"6month","weight":-0.0258},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"先声药业集团有限公司是一家从事药品的研发、生产和销售的公司。该公司的主要产品为仿制药，包括用于中枢神经系统疾病的产品必存、用于肿瘤疾病的产品捷百舒和捷佰立、以及用于自身免疫疾病的产品英太青。该公司还从事生产创新药，比如用于肿瘤疾病的恩度。该公司还从事为医疗机构销售的第三方药品提供推广服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.09318},{"month":2,"riseRate":0.666667,"avgChangeRate":0.070754},{"month":3,"riseRate":0.5,"avgChangeRate":-0.014037},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003707},{"month":5,"riseRate":0.666667,"avgChangeRate":0.105952},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032044},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.001102},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.059624},{"month":9,"riseRate":0.5,"avgChangeRate":-0.024901},{"month":10,"riseRate":0.8,"avgChangeRate":0.108743},{"month":11,"riseRate":0.666667,"avgChangeRate":0.044296},{"month":12,"riseRate":0.5,"avgChangeRate":0.000556}],"exchange":"SEHK","name":"先声药业","nameEN":"SIMCERE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"先声药业,02096,先声药业股票,先声药业股票老虎,先声药业股票老虎国际,先声药业行情,先声药业股票行情,先声药业股价,先声药业股市,先声药业股票价格,先声药业股票交易,先声药业股票购买,先声药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}